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Summary 
 
This guideline provides recommendations for the diagnostic and therapeutic 
procedures for patients with malignant gliomas. It differentiates evidence-based 
standards from reasonable options or non-evidence-based measures that should no 
longer be considered. The recommendations herein shall provide a framework and 
assurance for the choice of diagnostic procedures and therapeutic measures and aim 
to reduce complications from unnecessary treatment and cost. The guideline will 
contribute to a critical appreciation of concurrent medications with a focus on the 
controlled use of anticonvulsants and steroids. It shall serve as a guideline for all 
professionals involved in the diagnostics and care of glioma patients and also as a 
source of knowledge for insurance companies and other institutions involved in the 
cost regulation of cancer care in Europe. Implementation of the recommendations 
summarized here will require interdisciplinary structures of care for brain tumor 
patients and structured processes of diagnostic and therapeutic procedures. 
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Search strategy and selection criteria 
This guideline was prepared by a task force assembled by the Executive Committee 
of the European Association for Neuro-Oncology (EANO) in 2013. The task force was 
designed to represent the different disciplines involved in the diagnosis and care of 
malignant glioma patients as well as to reflect the multinational composition of EANO. 
References for this review were identified through searches of PubMed with the 
search terms “glioma”, “anaplastic”, “glioblastoma”, “trial”, “clinical”, “radiotherapy” 
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and “chemotherapy” from January 2005 to January 2013. Articles were also identified 
through searches of the authors` own files. Only papers in English were reviewed. 
Data available only in Abstract form were not included with one exception. The final 
reference list was generated on the basis of originality and relevance to the broad 
scope of this review. 
 
Introduction 
The current guideline on the diagnosis and treatment of gliomas follows the Third 
Revision of the World Health Organization (WHO) Histological Classification of 
Tumors of the Central Nervous System.1 It covers WHO grade III anaplastic 
astrocytomas, oligodendrogliomas and oligoastrocytomas, WHO grade IV 
glioblastomas including its variants, gliomatosis cerebri, and WHO grade III and IV 
gliomas of brainstem and spinal cord. The guideline covers prevention, early 
diagnosis and screening, therapy, follow-up and rehabilitation of patients with 
malignant gliomas. It does not cover differential diagnoses of gliomas and adverse 
effects of therapeutic measures in depth. The structure of the guideline was based on 
the national guideline on gliomas of the German Society of Neurology and the 
German Cancer Society (www.dgn.org). 
A Webappendix summarizes EANO`s recommendations for the general approach to 
patients with malignant gliomas with coverage of diagnostic aspects – early diagnosis 
and prevention, history, clinical examination, neuroimaging, cerebrospinal fluid 
analyses, electroencephalography, preoperative management, biopsy and resection, 
histological classification and grading, molecular diagnostics – as well as general 
recommendations for therapy - surgical therapy, radiotherapy (RT), pharmacotherapy 
and other therapeutic approaches. 
The guideline aims at serving medical professionals of all disciplines involved in the 
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diagnosis and care of glioma patients, in particular neurologists, neurosurgeons, 
radiation oncologists, neuropathologists, neuroradiologists, oncologists, pediatric 
oncologists, epileptologists, psycho-oncologists, rehabilitation specialists, palliative 
care and neurooncology nursing specialists. Further, the recommendations may 
serve as a valuable source of information for patients, relatives, other health 
professionals and health insurances. 
 
 
Specific recommendations 
 
Anaplastic astrocytoma – WHO grade III 
 
Anaplastic astrocytomas exhibit inhomogeneous density on CT and appear as 
hyperintense, space-occupying lesions on T2-weighted/fluid-attenuated inversion 
recovery (FLAIR) magnetic resonance imaging (MRI). They tend to show patchy 
enhancement upon contrast administration and commonly exhibit peritumoral edema. 
However, a significant proportion of up to 30% of these tumors may show no 
enhancement on CT or MRI. Abnormal vessels may be visualized by MRI 
angiography. Favorable prognostic factors include young age, high Karnofsky 
performance score (KPS), isocitrate dehydrogenase (IDH)-1/2 mutation, and 
O6-methylguanine DNA methyltransferase (MGMT) promoter methylation.2 Further, 
loss of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) expression 
defines a subgroup of anaplastic astrocytic tumors with a more favorable prognosis.3 
The traditional standard of care for anaplastic astrocytoma includes maximal 
resection as feasible or biopsy followed by involved-field RT to 60 Gy administered in 
1.8–2 Gy fractions (Table 1).4 Historical randomized clinical trials using this treatment 
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modality have confirmed a doubling of median survival time compared with surgery 
alone. An efficacy of adjuvant chemotherapy using nitrosourea compounds as a part 
of first-line treatment was suggested by meta-analysis, e.g., the 1-year survival rate 
was reported to be increased from 58% to 63%, and the 2-year survival rate from 
31% to 37% in a meta-analysis of published trials.5 However, such meta-analyses 
are potentially biased by a greater likelihood of negative trials not to be published. No 
survival benefit for the addition of procarbacine, 
1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and vincristine (PCV) 
chemotherapy to RT was demonstrated in the subgroup of anaplastic glioma patients 
in a large Medical Research Council (MRC) trial.6 Conversely, the German 
Neuro-Oncology Group (NOA)-04 trial indicated that alkylating agent chemotherapy 
alone using PCV or temozolomide (TMZ) was similarly effective as RT alone 
regarding progression-free survival, with overall survival data being similar, but not 
mature especially for the patients with good prognosis when first published.7 The 
CATNON trial (European Organization for Research and Treatment of Cancer 
(EORTC) 26053) was based on the assumption that adjuvant chemotherapy is not 
standard of care in 1p/19q-non-co-deleted tumors, the majority of which are 
anaplastic astrocytomas, and explores the added value of concomitant or adjuvant 
TMZ or both added to first-line RT. A retrospective analysis from NOA-04, NOA-08 
and the German Glioma Network suggested that the IDH-1/2 status might serve as a 
predictive biomarker for benefit from the addition of TMZ to RT: patients with 
IDH-1/2-wildtype tumors with a methylated MGMT promoter might benefit from the 
inclusion of alkylating agent chemotherapy in the first-line treatment.8 The present 
standard of care outside clinical trials, based on NOA-04,7 remains RT alone or 
alkylating agent chemotherapy alone for patients with anaplastic astrocytoma (which 
typically lacks 1p/19q co-deletion) until long-term results from NOA-04 and data from 
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CATNON become available. TMZ is commonly preferred over PCV because of 
favorable safety and tolerability profile. 
At progression the option of second surgery should be explored. Initial therapy 
determines the options at recurrence. For pre-irradiated patients, hypofractionated 
RT using, e.g., 6-7 × 5 Gy or 10-13 × 3 Gy may be feasible if recurrences are 
circumscribed and chemotherapy is contraindicated. Re-irradiation should be given 
as fractionated stereotactic RT, conformal RT with tight margins or image-guided 
radiotherapy (IGRT). However, the size and patterns of recurrent tumor often 
preclude re-irradiation, and the overall efficacy is disputed. Alkylating agent 
chemotherapy is the treatment of choice for most chemo-naive patients who progress 
after RT. TMZ and nitrosoureas are probably equally effective. A median 
progression-free survival of 23 weeks and a progression-free survival rate at 6 
months of 46% in a phase II setting led to the approval of TMZ in this indication;9 14 
of 111 patients in this study had anaplastic oligoastrocytoma. The comparative study 
of TMZ and a variant of the standard European PCV regimen (Table 2) confirmed 
similar efficacy.10 Bevacizumab is commonly used after failure of RT and alkylating 
agent chemotherapy, depending on local availability, with progression-free survival 
rates at 6 months of 20-60%.11-13 Controlled trials are missing, however, and there is 
no evidence to combine bevacizumab with cytotoxic agents in this setting. 
 
 
Anaplastic oligodendroglioma and oligoastrocytoma - WHO grade III 
 
The entity of anaplastic oligoastrocytoma remains a matter of debate for years and 
has been challenged because of poor interobserver agreement and incomplete 
molecular definition. In the NOA-04 trial which had central neuropathology review at 
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study entry,7 anaplastic oligodendroglioma and mixed anaplastic oligoastrocytoma 
shared the same, more favorable course than anaplastic astrocytoma. In the coming 
revision of the WHO classification, molecular markers should be integrated to refine 
the current morphology-based classification of anaplastic gliomas.2,3 Among 
anaplastic gliomas, there is high correlation between oligodendroglial morphology 
and the 1p/19q co-deletion. Tumors with 1p/19q co-deletion probably invariably carry 
IDH-1/2 mutations and frequently demonstrate MGMT promoter methylation as well 
as telomerase reverse transcriptase (TERT) promoter mutations.14 In contrast, TP53 
mutation and loss of ATRX expression are rare in 1p/19q-co-deleted gliomas, but 
common in diffuse and anaplastic astrocytomas. This may help to dissect the 
controversial entity of anaplastic oligoastrocytoma.3 
Extent of resection is a prognostic factor in these tumors, too.7,15 Although RT (54-60 
Gy, 1.8-2 Gy-fractions) has been considered standard of care for anaplastic 
oligodendroglial tumors, their chemosensitivity to nitrosoureas and TMZ has long 
been recognized, and ongoing controversies do not focus on whether to give RT or 
alkylating chemotherapy at all, but rather when and in what sequence. Long-term 
results of the two early large independent randomized clinical trials – EORTC 26951 
and Radiation Therapy Oncology Group (RTOG) 9402 – that explored the value of 
PCV polychemotherapy, either prior to or immediately after RT, indicate that the 
inclusion of chemotherapy in the first-line treatment confers a survival advantage 
which becomes evident only after follow-up of more than six years and only in the 
subgroup of patients with 1p/19q-co-deleted tumours.16-19 Thus, 1p/19q co-deletions 
have also predictive value for benefit from chemotherapy, in addition to the 
characterization of a prognostically more favorable subgroup of patients with 
anaplastic oligodendroglial tumors. Although these results mostly stem from 
retrospective analyses of small patient cohorts and are thus explorative, both studies 
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show very similar results in the patients with 1p/19q-co-deleted tumors and thus 
validate each other. Important questions remain, however, including: how many of 
the long-term survivors treated with RT plus PCV experienced preserved cognitive 
function and quality of life? Could the same improvement in overall survival have 
been achieved with the combination of RT and TMZ or even with alkylating agent 
chemotherapy alone? Long-term results from the NOA-047 trial which compared RT 
versus TMZ versus PCV alone might shed light on some of these questions. At 
present, phase III clinical trials in patients with 1p/19q-co-deleted oligodendroglial 
tumors should include RT plus PCV as a standard arm. In clinical practice, many 
sites have reverted to classical RT plus PCV as a standard of care, others prefer 
TMZ/RT→TMZ or even TMZ alone in particular in young patients (Table 2, 
Supplementary Figure). Accordingly, the amended 3-group CODEL trial shall now 
compare RT→PCV with TMZ/RT →TMZ) and TMZ alone. 
Treatment at progression is influenced by type of and response to first-line treatment 
as outlined for anaplastic astrocytoma. If neither RT nor alkylating agents are options 
because they failed or because of intolerance, bevacizumab can be considered as a 
salvage strategy, depending on local availability.11,13,20,21 Proper controlled studies 
are lacking here, however, and there is also no evidence to combine bevacizumab 
with cytotoxic agents in this setting. 
 
 
Glioblastoma (WHO grade IV) 
 
Glioblastomas are space-occupying lesions on MRI or CT which exhibit irregular 
boundaries and commonly enhance after administration of contrast agents. Central 
necrosis and perilesional edema are common. Angiography shows highly abnormal 
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vasculature with arteriovenous shunting and early venous drainage. Interestingly, in 
the growing population of elderly patients with malignant gliomas, there is no major 
difference in prognosis between anaplastic astrocytoma and glioblastoma.22-24 
The therapeutic role of surgery is no longer disputed. A small randomized trial from 
Finland in glioblastoma or anaplastic astrocytoma patients aged > 65 showed a 
median survival of 171 days after resection versus 85 days after biopsy (p=0.035).25 
This study has been criticized because of small patient numbers (n=30 enrolled, 13 
versus 10 patients per arm evaluable) and major KPS imbalances between arms. 
While some recent clinical series have reported gradually extended survival 
associated with extent of resection, other studies proposed that only a gross total 
resection is associated with better outcome.26 Meanwhile many tools are available to 
increase the extent of resection while keeping the risk of new neurological deficits low. 
These include the routine use of surgical navigation systems housing functional MRI 
datasets when available, intraoperative MRI and intraoperative functional monitoring. 
The fluorescent dye, 5-aminolevulinic acid (ALA) helps to visualize glioblastoma 
tissue during microsurgical tumor resection. Its use was associated with an increased 
rate of gross total resections and an increased progression-free survival rate at 6 
months.27 Whether its use prolongs survival remains unknown,28 moreover, the 
pivotal study was performed before TMZ/RT→TMZ became standard of care. 
RT has been standard of care for glioblastoma for decades, with an undisputed major 
survival benefit.4 The RT volume commonly includes the T1-enhanced region plus a 
2-3 cm safety margin on the T2 or FLAIR abnormality planned as described above. 
The standard dose is 54-60 Gy administered in 1.8-2 Gy fractions. A regimen of 50 
Gy in 1.8 Gy fractions was superior to best supportive care in patients 70 years or 
older.29 Patients with adverse prognostic factors defined by age or performance 
status or both are now commonly treated with hypofractionated RT, e.g., 40 Gy in 15 
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fractions.30 In the elderly, this is now the preferred regimen for patients with tumors 
lacking MGMT promoter methylation.23,31 Neither accelerated hyper- nor 
hypofractionated regimens nor brachytherapy nor radiosurgery or a stereotactic RT 
boost have been shown to be superior to standard fractionation in terms of survival.  
The combination of nitrosourea-based chemotherapy with RT in newly diagnosed 
glioblastoma increased the 1-year survival rate from 31% to 37% and the 2-year 
survival rate from 9% to 13% in a meta-analysis.5 No differences between single 
nitrosourea compounds or between monotherapy and nitrosourea-based combination 
therapies were identified. The British study comparing RT alone with RT plus PCV 
showed no increase of survival with the addition of chemotherapy.6 Local 
1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) wafer chemotherapy added to RT 
conferred a survival benefit of 13.9 over 11.6 months over RT alone for the 
intention-to-treat population, but the difference was no longer significant when 
patients with anaplastic gliomas were removed from the cohorts.32-34 Its efficacy and 
safety in combination with TMZ/RT→TMZ have not been adequately explored. 
Concomitant and adjuvant TMZ chemotherapy plus RT (TMZ/RT→TMZ) is the 
standard of care for adult patients with newly diagnosed glioblastoma aged up to 70 
and in good general and neurological condition.35,36 The benefit from TMZ is most 
prominent in patients with glioblastoma with MGMT promoter methylation.37,38 TMZ is 
given at 75 mg/m2 during RT and for six maintenance cycles on 5 out of 28 days at 
150-200 mg/m2 thereafter. There is no benefit from increasing the dose of TMZ in the 
setting of newly diagnosed disease39 and extending the duration of chemotherapy 
beyond 6 cycles is also not supported by clinical trial data. For individual patients, 
increasing the number of adjuvant TMZ cycles may be considered, e.g., for individual 
patients with stable or incompletely regressing, residual, contrast-enhancing tumors 
at completion of 6 cycles of TMZ. 
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Two randomized trials conducted in the adult glioblastoma patient population have 
demonstrated a gain in progression-free survival of 3-4 months, but not overall 
survival, when patients with newly diagnosed glioblastoma received bevacizumab in 
addition to TMZ/RT→TMZ.40,41 Interpretation of the data from these trials remains 
controversial,42 and a decision on approval in newly diagnosed glioblastoma in 
Europe is pending. 
For the increasing population of elderly patients with glioblastoma, new standards of 
care were defined in 2012. Based on the NOA-08 and Nordic trials,23,31 MGMT 
testing should be considered standard practice.43 Patients with tumors lacking MGMT 
promoter methylation should receive hypofractionated RT alone. This is also the 
preferred treatment for patients with tumors with unknown MGMT status. Those with 
tumors with MGMT promoter methylation should be treated with TMZ alone (5/28 
until progression or for 12 months) or with TMZ/RT→TMZ. The role of early RT in 
addition to TMZ in these patients will be better understood when data from the 
ongoing EORTC National Cancer Institute of Canada (NCIC) Clinical Trial Group 
elderly trial can be compared with those of the NOA-08 and Nordic trials.  
Best supportive care may the preferred option in patients with large or multifocal 
lesions with KPS below 50, notably in patients who cannot provide informed consent 
for further therapy beyond biopsy. 
Standards of care for patients with recurrent glioblastoma are not well defined and 
clinical decision making is commonly based on prior treatment, age, KPS, prior 
therapy, and patterns of relapse. Second surgery should typically be considered with 
large, but circumscribed lesions causing neurological deficits and when the interval 
from last surgery is more than 6 months. However, surgery for progressive 
glioblastoma may also be considered earlier in symptomatic patients, especially in 
patients with suboptimal initial surgery. Approximately 20-30% of patients with 
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recurrent glioblastoma are candidates for second surgery. The role of re-irradiation is 
uncertain, including the role of amino acid positron emission tomography (PET) for 
target delineation, and multiple fractionation regimens have been proposed, e.g., 
from 6 x 5 Gy to 18 x 2 Gy.44,45 The three strategies of medical treatment for 
glioblastoma recurring after TMZ/RT→TMZ most commonly used across Europe 
include nitrosourea-based regimens, alternative dosing regimens of TMZ, and 
bevacizumab. The activity of CCNU has been confirmed in the standard arms of 
randomized trials exploring the activity of the protein kinase C-β inhibitor, 
enzastaurin,46 or the vascular endothelial growth factor (VEGF) receptor inhibitor, 
cediranib,47 with progression-free survival rates at 6 months of 20%. Somewhat 
better control rates at 6 months have been reported with a continuous dosing 
regimen of TMZ,48 but not in recent phase II trial exploring a 21 out of 28 days 
schedule.49 The BR12 trial which enrolled recurrent, TMZ-naïve malignant glioma 
patients provided no evidence for superiority of dose-intensified TMZ over 
standard-dosed TMZ,50 but these data are of limited value in assessing the role of 
TMZ rechallenge for patients pre-exposed to TMZ. They do, however, suggest that 
there is no rationale for using dose-intensified TMZ in recurrent glioma patients who 
are TMZ-naive. 
Bevacizumab has been approved for the treatment of recurrent glioblastoma in 
various countries throughout the world, but not in the European Union, based on two 
prospective, but uncontrolled phase II trials that reported radiological response rates 
of 30% or more and progression-free and overall survival times interpreted to be 
superior to historical controls.51,52 A value of bevacizumab in the management of 
progressive malignant gliomas in clinical practice is almost universally accepted 
because of evident, albeit transient, symptom relief and steroid-sparing effects. 
However, timing and dosing schedules remain controversial, and an effect on overall 
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survival remains to be demonstrated. No active combination partner for bevacizumab 
has been identified in the setting of progressive disease, albeit in uncontrolled or 
non-comparative trials, suggesting that bevacizumab monotherapy should be 
administered outside clinical trials. Preliminary data indicate that the combination of 
bevacizumab and CCNU may be superior to either agent alone,53 suggesting that this 
combination warrants further exploration as planned in a phase III trial by the 
EORTC. 
 
 
Gliomatosis cerebri 
 
The diagnosis of gliomatosis cerebri is based on the histological verification of a 
glioma and requires the radiological demonstration of diffuse signal alteration 
suggestive of tumor affecting at least three cerebral lobes. The diagnosis is thus not 
based on histology alone and hence rather operational. Typically, the tumor involves 
both cerebral hemispheres and may extend into the basal ganglia and brain stem. 
Gliomatosis cerebri may correspond to WHO grades II, III or IV, based on the 
histological findings in the respective biopsy specimens. The diagnostic concept of 
gliomatosis cerebri has proven difficult to operationalize in clinical practice and trials 
and is likely to be revised with support of molecular markers and advanced imaging 
technology. The imaging features are quite characteristic and include a diffuse 
hyperintense tumor on T2 / FLAIR images involving both the white and gray matter, 
non-enhancing or with small patchy areas of contrast enhancement. Perfusion MRI 
and MR spectroscopy can be useful to differentiate rare non-neoplastic lesions. 
Gliomatosis cerebri imaging resembles diffuse (WHO grade II) astrocytomas in most 
patients, but the median survival is in the range of only 30 months for patients eligible 
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for a clinical trial.54 In selected patients where intracranial pressure is markedly 
elevated, decompressive craniectomy may rarely be considered at the time of biopsy 
to prevent rapid neurological deterioration. The course is highly variable, but 
occasionally younger patients can be followed for years without specific therapy. 
IDH-1/2 mutations are associated with a better outcome. Surgery is commonly limited 
to a diagnostic biopsy. RT and alkylating chemotherapy are active treatments. The 
role of RT as initial treatment is limited because of the high dose required for the 
control of glioma growth and the large target volumes required in gliomatosis cerebri. 
Both PCV and TMZ are commonly used as alternatives to RT.55,56 The NOA-05 trial 
explored the efficacy of primary PC chemotherapy, omitting vincristine because of 
poor blood brain barrier penetration, and observed treatment failure at 8 months in 
less than half of the patients, and a median overall survival of 30 months.54 
 
Brain stem gliomas and spinal gliomas 
 
Diffuse intrinsic pontine gliomas are a major challenge in pediatric neuro-oncology. 
While children are often treated based on neuroimaging alone, histological 
verification of the diagnosis is considered mandatory in adults, especially in case of 
enhancing lesions, because of a higher error rate by imaging alone and a broader 
range of differential diagnoses.57 Magnetic resonance spectroscopy can aid 
differential diagnosis if biopsy is not considered feasible or declined. Anaplastic 
gliomas and glioblastomas of brain stem and spinal cord are rare and no data from 
clinical studies are available. Resection is limited to exophytic tumors because of the 
expected neurological deficits with surgery in the brainstem and spinal cord. RT is the 
standard of care, and TMZ or nitrosoureas or bevacizumab may be employed in the 
course of disease following the considerations outlined above for supratentorial 
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tumors of the same WHO grades.58 
 
 
Monitoring and follow-up 
Whenever feasible, MRI should be used to monitor the efficacy of pharmacotherapy 
or as surveillance imaging after completion of treatment.59 Intervals of 3 months are 
recommended for most patients with malignant gliomas, although longer intervals 
may be considered for patients with prolonged disease control, notably young 
patients with 1p/19q-co-deleted oligodendroglial tumors. 
 
 
Supportive care and patient management 
 
Raised intracranial pressure 
 
Raised intracranial pressure due to growth of a glioma is an emergency situation that 
requires immediate intervention, commonly using high doses of steroids and less 
commonly osmotic agents. Acute surgical decompression is rarely required. Whether 
decompressive surgical interventions make sense in the further course of disease 
once the diagnosis has already been established and primary therapy administered, 
requires consideration of the options for further treatment after the surgical 
intervention. 
 
Thromboembolic events 
 
Glioma patients are at increased risk of thromboembolic events throughout the 
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course of disease for many reasons, including: motor deficits, steroid medication, RT, 
chemotherapy, immobility, and release of vasoactive molecules from glioma cells. 
The significance of this comorbidity increases with the use of antiangiogenic agents 
as therapeutics against gliomas because these agents are also associated with the 
risk of ischemic and hemorrhagic vascular events. Although anticoagulation using 
coumadin derivatives is feasible in glioma patients, low molecular weight heparins 
are often preferred for a favorable safety profile.60 A single study on primary 
prophylaxis using such agents was prematurely stopped, but provided no evidence 
for a decreased incidence of first thromboembolic events.61 Vena cava filters may be 
an option for patients who cannot be anticoagulated. 
 
Epilepsy 
 
Glioma patients who never suffered symptomatic seizures should not receive primary 
prophylaxis with anticonvulsant drugs.62 A single seizure usually necessitates the 
institution of drug treatment until the underlying tumor growth is controlled by 
tumor-specific therapy.63 If no further seizure occurs after surgery and the tumor 
appears to be controlled by treatment, tapering of anticonvulsants should be 
attempted within the first weeks or months after surgery and further tumor-specific 
therapy. Recurrent seizures after surgery usually indicate life-long need for 
anticonvulsants. The choice of drug for patients requiring secondary prophylaxis is 
guided by various considerations.64,65 The classical drugs include carbamazepine, 
valproic acid and phenytoin and are of similar efficacy. All anticonvulsants are 
associated with relevant toxicities in brain tumor patients. Phenytoin and 
carbamazepine share an unfavorable side effect profile, including drug interactions, 
and are therefore not suited for long-term therapy of brain tumor patients. Moreover, 
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carbamazepine is not available i.v. and commonly induces vertigo and nausea upon 
initial dosing, notably in elderly patients. Long-term administration impairs cognitive 
function. The enzyme-inducing properties of phenytoin, carbamazepine and 
barbiturates may decrease the activity of many chemotherapeutic agents whereas 
enzyme-inhibitory properties of valproic acid may accentuate toxicity from, and 
possibly activity of, chemotherapy, e.g., valproic acid-treated patients had superior 
outcome, but also experienced increased hematological toxicity, in the experimental 
arm of the EORTC NCIC TMZ trial.66 Agents such as levetiracetam, gabapentin, 
lamotrigin or topiramate offer advantages compared with the classical agents, mainly 
because of lack of drug interactions. In particular levetiracetam is often preferred 
because of good tolerability, rapid dosing, and intravenous availability. Lamotrigine is 
an attractive alternative if slow dosing is an option. Lacosamide and perampanel are 
new drugs that reqire investigation in brain tumors. Clonazepam and other 
benzodiazepines should only be used transiently, e.g., during dosing of lamotrigine. 
This document does not address the competence to drive with a brain tumor because 
this is subject to country-specific regulations which are beyond the scope of this 
guideline. 
 
Steroids 
 
The need to continue steroid treatment in brain tumor patients should be critically 
reviewed at each visit because of the major burden of side effects with an impact on 
quality of life and the potential interference with tumor-specific therapies. Drug 
interactions, increased risk of infection and thrombosis, myopathy, and depression 
are only a few of the frequently observed side effects. The option to taper steroids 
rapidly after tumor debulking should not be missed. Patients who have undergone 
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significant resection often tolerate RT with no steroids, or else a modest dose in the 
first week. Patients who have undergone biopsy only may require steroids at the start 
of RT, but moderate doses (4-8mg daily) will suffice, and can often be tailed off 
during or soon after treatment. Bevacizumab is a powerful steroid-sparing agent, but 
should not be used solely for this purpose. Other approaches to replace steroids as 
anti-edema agents in neuro-oncology are being explored. 
 
Psychological and social support 
 
Psychological stress and the social impact of the disease affecting patients and their 
families and caregivers must not be underestimated. Psychiatric comorbidity should 
be actively explored and treated accordingly, employing both psychotherapy and 
pharmacotherapy.67 Recognition of the social impact of having a brain tumor and 
adequate counseling in such circumstances are an integral aspect of care for brain 
tumor patients. The impact of therapy in this patient population with limited life span 
must also be considered.68 Diverse support may be beneficial from individuals such 
as neuro-oncology nurse specialists, social workers, counselors, clinical 
psychologists, palliative medicine professionals, and patient focus groups. 
 
Rehabilitation 
 
The need for rehabilitative measures should be explored during and after 
tumor-specific therapy. Type and intensity of these measures depend not only on 
cognitive and neurological function, but also on age and expected course of disease. 
In-patient and out-patient rehabilitation are options. Amelioration of neurological and 
neuropsychological deficits are the main goals of neurological rehabilitation in brain 
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tumor patients. Coping strategies for living with a malignancy is the main goal for 
rehabilitation with a psychological focus. 
 
Palliative care 
 
The appropriate timepoint and setting for communicating the foreseeable restrictions 
and limitations of tumor-specific measures needs to be carefully assessed and not 
taken too late in the course of the disease. During advanced stages of disease 
specific anti-neoplastic treatments may no longer be warranted and palliative care 
concepts acquire major significance. This calls for a stronger involvement of 
specialized nurses, social workers and a coordination of care at home or in another 
adequate setting.69 Important pharmacological measures include the use of 
antiemetics, analgesics, corticosteroids and anticonvulsants. If swallowing difficulties 
are expected, patients and caregivers should be instructed on how to administer 
medication, notably sublingual or rectal anticonvulsants. Fluid replacement may 
become necessary. In the terminal stage, analgesics and sedatives should be 
provided in sufficient doses. Support to find the best individual setting of dying should 
be offered and a strategy for the last phase of the illness discussed together with 
patients and caregivers at an appropriate stage. 
 
Coordination of care 
 
Clinical decision making for patients with malignant gliomas should ideally be based 
on interdisciplinary tumor board recommendations from the first diagnostic and 
therapeutic decisions onwards. Such boards may also be the ideal forum to discuss 
which parts of the treatment plan can be realized locally, which parts require a 
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specialized center, which measures require in-patient versus out-patient settings, and 
what intensity of neurorehabilitative measures is in the patient`s interest. Local and 
national guidelines may serve for orientation beyond this guideline. 
 
Outlook 
Guidelines reflect the state of knowledge at a given timepoint. Table 3 summarizes 
the key recommendations of the EANO task force in 2013. The EANO website 
(www.eano.eu) will inform of future updates on this guideline. 
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Table 1 - Management options for newly diagnosed and progressive malignant 
gliomas 
 
Tumor Newly diagnosed Progression 
   
Anaplastic astrocytoma 
WHO grade III 
Resection or biopsy and 
radiotherapy or 
chemotherapy (or combined 
modality treatment) 
Resection and 
chemotherapy or 
radiotherapy or 
bevacizumab 
   
Anaplastic 
oligodendroglioma or 
oligoastrocytoma WHO 
grade III with 1p/19q 
co-deletion 
Resection or biopsy and 
chemotherapy with (or 
without) radiotherapy 
Resection and 
chemotherapy or 
radiotherapy or 
bevacizumab 
   
Anaplastic 
oligodendroglioma and 
oligoastrocytoma WHO 
grade III without 1p/19q 
co-deletion 
Resection or biopsy and 
radiotherapy or 
chemotherapy (or combined 
modality treatment) 
Resection and 
chemotherapy or 
radiotherapy or 
bevacizumab 
   
Glioblastoma WHO grade 
IV  
(< 65-70 years) 
Resection or biopsy and 
radiotherapy plus TMZ 
(TMZ/RT→TMZ) 
Re-resection, 
re-irradiation, 
chemotherapy 
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Tumor Newly diagnosed Progression 
(rechallenge), 
bevacizumab 
   
Glioblastoma WHO grade 
IV  
(> 65-70 years) 
Resection or biopsy and 
radiotherapy or TMZ (± 
radiotherapy) based on 
MGMT and performance 
status 
Resection and 
chemotherapy or 
radiotherapy 
 
Table 2 - Chemotherapy protocols in malignant gliomas 
 
Protocol Dose and mode of administration 
TMZ 150–200 mg/m2 D1- D5 p.o. x 4 weeks 
ACNU, BCNU, CCNU* Different regimens,e.g., CCNU p.o. 110 mg/m2 every 6 
weeks 
PCV Procarbazine 60 mg/m2 p.o. D8–D21  
CCNU 110 mg/m2 p.o. D1 
Vincristine 1.4 mg/m2 i. v. (maximum 2 mg) D8 +D29 x 
(6-)8 weeks 
Bevacizumab 10 mg/m2 x 2 weeks or 15 mg/m2 x 3 weeks 
*ACNU, 1-[(4-Amino-2-methylpyrimidin-5-yl) methyl]-3-(2-chlorethyl)-3-nitrosourea 
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Table 3 - Key recommendations* 
 
General C L 
Karnofsky performance score (KPS), neurological function, age, and 
individual risks and benefits need to be considered for clinical decision 
making in Neuro-Oncology. 
I A 
Screening and prevention have no major role in malignant gliomas. IV - 
Patients with suspected hereditary cancer syndromes should receive 
genetic counselling and based on that might be referred for molecular 
genetic testing. 
IV - 
The diagnostic imaging approach of first choice is magnetic resonance 
imaging (MRI) without and with contrast enhancement. 
IV - 
An apparent increase of tumor volume on neuroimaging in the first 
months after local therapeutic interventions including radiotherapy and 
experimental local treatments may reflect pseudoprogression. 
II B 
Clinical decision making without obtaining a definitive histological 
diagnosis at least by biopsy should occur only in very exceptional 
situations. 
IV - 
Histological diagnoses should follow the current WHO classification of 
tumors of the central nervous system. 
IV - 
Three molecular markers (1p19q co-deletion, MGMT promoter 
methylation, IDH-1/2 mutation) are valuable prognostic markers. A role 
II A 
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for clinical decision making is currently largely limited to MGMT promoter 
methylation in elderly glioblastoma patients and 1p19q co-deletion in 
patients with anaplastic oligodendroglial tumors. 
The prevention of new permanent neurological deficits has higher priority 
than extent of resection in the current surgical approach to gliomas. 
IV - 
   
Anaplastic gliomas (WHO grade III)   
Standard of care for anaplastic astrocytoma includes resection as 
feasible or biopsy followed by involved field radiotherapy. 
I A 
Based on the NOA-04 trial, chemotherapy using TMZ or the PCV regimen 
are as effective as radiotherapy in the treatment of anaplastic gliomas 
including anaplastic astrocytomas. 
II B 
Based on the EORTC 26951 and RTOG 9402 trials, patients with 
1p/19q-co-deleted anaplastic oligodendroglial tumors should not be 
treated with radiotherapy alone, but alkylating agent chemotherapy with 
(or without) radiotherapy. 
II B 
Temozolomide chemotherapy is standard treatment at progression after 
surgery and radiotherapy. 
I A 
Based on the NOA-04 trial, anaplastic oligoastrocytomas of WHO grade 
III are treated as anaplastic oligodendrogliomas. 
II B 
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Glioblastoma (WHO grade IV)   
Standard of care for glioblastoma (age < 65-70 years) includes resection 
as feasible or biopsy followed by involved-field radiotherapy and 
concomitant and maintenance (6 cycles) TMZ chemotherapy 
(TMZ/RT→TMZ) (EORTC 26981 NCIC CE.3). 
I A 
Elderly patients not considered candidates for TMZ/RT→TMZ should be 
treated with radiotherapy (e.g., 15 x 2.66 Gy) or TMZ (5/28) based on 
MGMT promoter methylation status (NOA-08, Nordic Trial). 
I A 
At recurrence, standards of care are less well defined. Nitrosourea 
regimens, TMZ rechallenge and, with consideration of the 
country-specific label, bevacizumab are options of pharmacotherapy. 
When available, recruitment into appropriate clinical trials should be 
considered. 
II B 
 
*C class of evidence, *level of recommendation70 
 
 
WEBAPPENDIX 
 
This webappendix summarizes EANO`s recommendations for the general approach to patients with malignant 
gliomas with coverage of diagnostic aspects – early diagnosis and prevention, history, clinical examination, 
neuroimaging, cerebrospinal fluid analyses, electroencephalography, preoperative management, biopsy and 
resection, histological classification and grading, molecular diagnostics – as well as general recommendations 
for therapy - surgical therapy, radiotherapy, pharmacotherapy and other therapeutic approaches. 
 
 
Diagnostics 
 
Early diagnosis and prevention 
The annual incidence of malignant gliomas is approximately 4-5/100,000. Simple serum tests as a screening tool 
for early diagnosis are not available, instead, neuroimaging, preferably magnetic resonance imaging (MRI), is 
necessary to detect even early lesions. Anecdotal clinical evidence indicates that glioblastomas may evolve 
within few months, further supporting that early diagnosis and screening are not feasible at a population level 
and should therefore be restricted, if recommended at all, to individuals at genetic risk, e.g., patients with 
neurofibromatosis types I and II or Li Fraumeni syndrome. Whether such patients should undergo repeated 
neuroimaging in the absence of new neurological symptoms or signs, remains uncertain. 
 
History 
History taking will determine the first symptoms and signs attributable to the tumor and their evolution. It may 
disclose risk factors such as evidence for hereditary cancer predisposition, history of previous irradiation to the 
nervous system, immune deficiency, alcohol or other drug abuse, or other conditions associated with brain 
tumors or their differential diagnoses. Depending on neurocognitive function at presentation, history taking from 
relatives may provide valuable information. Clinical features suggestive of a brain tumor include manifestation 
of a seizure disorder, focal neurological signs, personality changes and ultimately symptoms and signs of 
increased intracranial pressure. 
 
Clinical examination 
The physical examination is done with specific consideration of the differential diagnosis of a metastatic tumor 
with a primary site outside the CNS and possible risks for neurosurgical intervention. The neurological 
examination documents neurological deficits caused by the tumor at presentation and is important as a baseline 
for monitoring the future course of disease and complications from treatment. A formal neuropsychological 
assessment in addition to Karnofsky performance score (KPS) and Minimental State Examination (MMSE) is 
recommended. As a minimum requirement, KPS and MMSE should be documented. 
 
Neuroimaging 
Whenever feasible, MRI without and with contrast enhancement is the investigation of choice when an 
intracranial tumor is suspected. In specific situations, additional diagnostic measures may be requested, e.g., 
cranial computed tomography (CT) to better delineate calcifications, angiography for surgical planning, or 
aminoacid positron emission tomography (PET) to select the most active tumor region for biopsy. The 
aminoacid tracers 18F-fluoroethyltyrosine (FET) and 11C-methionine (MET) provide a better signal-to-noise ratio 
in the brain than fluorodeoxyglucose (FDG).1 Neuroimaging, preferentially MRI, is also the most important 
measure to monitor response to therapy and course of disease, preferably based on standardized criteria which 
are under continuous development.2 Ideally patients should be on stable steroid doses for at least 5 days prior to 
imaging. When tumors are located within, or adjacent to eloquent brain regions and functional tracts, functional 
MRI (fMRI) and white matter tractography may help to assess the feasibility of surgery and serve as a guide to 
planning the operation. The role of further imaging techniques including perfusion MRI, single photon emission 
computed tomography (SPECT), and magnetic resonance spectroscopy (MRS) in routine clinical care still needs 
to be defined. MRS measures the concentration and spatial distribution of metabolites like choline or N-
acetylaspartate. A choline/ N-acetylaspartate ratio ≥2 indicates increased cellular proliferation and reduced 
neuron density and highlights metabolically active part of the tumor in high-grade gliomas.3 This metabolic ratio 
has been shown to predict survival4 and relapse location in glioblastoma.5 
Pseudoprogression, an apparent increase of the tumor volume on contrast-enhanced neuroimaging, in the 
absence of new lesions and often without clinical deterioration, may represent a major diagnostic challenge 
notably within the first months after the completion of radiotherapy or after experimental local surgical 
interventions.6 In cases of possible pseudoprogression, current treatment (if any) should not be stopped and 
earlier follow-up imaging at 4-8 week interval should be considered, taking into consideration the clinical 
condition. Failure to recognize pseudoprogression carries the risk of stopping a potentially effective treatment 
regimen, and instituting a salvage treatment that is not needed and the efficacy of which will be overestimated, 
given the spontaneous resolution of pseudoprogression. Conversely, the introduction of antiangiogenic agents 
has also led to the recognition of pseudoresponses if response assessment is solely based on contrast-enhanced 
scans, a phenomenon also addressed by the Response Assessment in Neuro-Oncology (RANO) group.2 A 
pseudoresponse typically is characterized by decreased contrast enhancement, but stable or increased T2 or 
FLAIR abnormality frequently associated with restriction of diffusion on diffusion-weighted imaging (DWI). 
 
Cerebrospinal fluid (CSF) analyses 
CSF analyses are of limited overall value in the differential diagnosis of brain tumours in adults, and lumbar 
puncture is contra-indicated in patients with raised intracranial pressure, notably with posterior fossa lesions. 
Glioma cells are rarely detected in the CSF, even when using sensitive techniques in patients with MRI-
documented leptomeningeal seeding, but occasionally CSF analysis may help to distinguish gliomas from other 
brain tumors, e.g., primary cerebral lymphomas, germ cell tumors or metastatic brain tumors, or inflammatory 
conditions. 
 
Electroencephalography (EEG) 
EEG may serve as an indicator of seizure risk and may be useful in monitoring pharmacotherapy in patients with 
tumor-associated symptomatic epilepsy or for the differential diagnosis of rapid decline or changes in 
neurocognitive function or vigilance. 
 
Preoperative management 
Prior to brain tumor surgery, unless there are contraindications or the suspicion of primary cerebral lymphoma or 
inflammatory lesions such as vasculitis or sarcoidosis, corticosteroids are commonly administered to decrease 
tumor-associated edema. The pre-operative use of steroids should be guided by the patients’ symptoms. Many 
patients will require a very low dose of steroids, if any, prior to surgery. Additional pharmacological measures 
such as osmotic agents, e.g., mannitol, are rarely necessary unless the patient presents with an acute deterioration 
due to increased intracranial pressure or mass effect. Dexamethasone is the most widely used steroid, has a long 
half-live and can be given as an intravenous bolus of up to 40 mg in patients with severely elevated intracranial 
pressure and then orally at up to 16 mg daily pre and during surgery. A single administration in the morning 
suffices, given the long half-life, and steroids should be tapered after surgery as feasible. The shorter the patients 
have received steroids and the lower the doses were, the quicker can they be withdrawn. 
Glioma patients who have suffered epileptic seizures at presentation should receive anticonvulsant drugs 
preoperatively. Agents available as intravenous preparations such as levetiracetam, valproic acid, phenytoin or 
benzodiazepines are often preferred in the acute phase. There is no evidence for a higher rate of perisurgical 
bleeding complications with valproic acid prophylaxis,7 but valproic acid is nevertheless avoided for that fear by 
many neurosurgeons. Phenytoin is no longer recommended because of its side effect profile and drug 
interactions. Given the trend towards earlier postoperative extubation, the advantage of intravenous availability 
is currently loosing significance, and other, solely oral agents may also be considered as agents of first choice.8 
 
Biopsy/resection 
The establishment of a specific neuro-oncological management concept requires a microscopic morphological 
diagnosis of the tumor tissue complemented by an increasing panel of molecular genetic markers. Surgical 
interventions in glioma patients are thus commonly both diagnostic and therapeutic measures. Because of the 
relevant, although rare differential diagnoses and the psychological burden of a mere imaging-guided tumor 
diagnosis, watch-and-scan strategies or palliative care only strategies without histological verification of the 
diagnoses should be exceptional. They are justified only if the risk of the biopsy procedure is thought to 
outweigh the gain of information gathered by the intervention or if the prognosis of the patient is too poor, i.e., 
elderly patients with extensive disease burden and deteriorating performance status. A stereotactic biopsy with 
local anesthesia can be safely performed even in frail patients to obtain a definitive diagnosis which is commonly 
helpful in guiding patients and relatives in situations where no further tumor-specific therapy will be instituted. 
To be fully informative, serial samples along the trajectory should be acquired during stereotactic biopsy, 
necessitating an experienced team of surgeons and neuropathologists. This is because tumors may be 
heterogeneous histologically, with astrocytic and oligodendrocytic features in different regions and different 
grades of malignancy in distinct areas. Definitive diagnoses should be obtained accordingly in more than 90% of 
the patients, with morbidity of 3-4% and mortality below 1%. Molecular analyses are possible even in these 
small specimens. Since markers like isocitrate dehydrogenase (IDH)-1/2 mutation, loss of heterozygosity (LOH) 
1p/19q and methylation of the MGMT promoter are homogeneously distributed within the solid tumor tissue, the 
risk of a sampling error is low as long as vital tumor tissue samples are available for molecular analysis.9,10 
Undergrading because of sampling error should be considered if neuroimaging suggests a higher grade of 
malignancy than the histological findings. 
Type and extent of neurological deficits and the likelihood of their improvement are important considerations 
when planning a surgical procedure for glioma patients. Although extent of resection is considered a prognostic 
factor for all malignant gliomas, this has been most convincingly demonstrated for complete resections of 
contrast-enhancing tumor verified by early postoperative imaging.11,12 The risk of complications from surgery is 
likely to vary with the caseload of the institution and the individual experience of the surgeon. There is 
consensus that new neurological deficits should be avoided and are not justified to achieve a greater extent of 
resection. The general condition including age, comorbidity and co-medication contributes to the overall surgical 
risk. 
 
Histological classification and grading 
During a surgical procedure it needs to be ascertained that adequate tissue has been obtained. This can be 
accomplished either by intraoperative cytological assessment when a neuropathologist is present in the operating 
theatre or by rapid section assessment before the surgical procedure is terminated. The tissue is assessed 
macroscopically to identify and label central tumor parts and infiltration zones. Part of the sample is formalin-
fixed and embedded in paraffin for conventional histological stainings, including a routine hematoxylin-eosin 
staining as well as additional histochemical and immunohistochemical analyses. Ideally, part of the tissue is also 
cryopreserved either for immediate or delayed molecular marker studies. 
The diagnostic process follows the WHO classification and consists in histological tumor typing as well as tumor 
grading using the four-tiered WHO grading scheme from WHO grade I to WHO grade IV which was designed to 
provide clinicians with information on the tumor's biological behavior and consequently the patient's prognosis 
and outcome. Cellular and nuclear atypia, high cellularity, increased mitotic activity, pathological mitoses, 
microvascular proliferation and necrotic areas serve as important features to assign a higher grade of malignancy 
in gliomas.13 Special neurohistological stains as well as immunohistochemical studies supplement the diagnostic 
process. These include connective tissue stains, e.g., Elastica-van-Gieson and trichrome staining of Masson, for 
the differentiation of mesodermal and glial tumors, as well as silver stain for the same purpose and for the 
differentiation of cerebral lymphomas. Common immunohistochemical markers for gliomas include glial 
fibrillary acidic protein (GFAP) and protein S100. In contrast, gliomas are negative for epithelial markers 
(cytokeratins) and lymphocytic markers (CD20, CD45) which differentiates metastatic carcinomas and 
lymphomas. Further, melanomas, meningiomas, sarcomatous tumors and germ cell tumors can be distinguished 
from gliomas based on specific marker profiles. In contrast, among the gliomas, there are no specific 
immunohistochemical markers to differentiate between astrocytic, oligodendroglial and oligoastrocytic tumors. 
GFAP expression is usually more prominent in astrocytic gliomas than in oligodendrogliomas. 
Immunohistochemical detection of mutant IDH-1R132H protein aids in the identification of diffuse astrocytic and 
oligodendroglial gliomas and their separation from other tumors and from reactive gliosis. Quantification of the 
proliferation-associated nuclear antigen Ki-67 using the MIB1 antibody is commonly used to characterize 
proliferative activity as a surrogate marker of growth and may aid tumor grading. 
 
Molecular diagnostics 
The molecular profiling of gliomas is currently based mainly on three markers which are highly relevant for 
diagnostic purposes and clinical decision making: 1p/19q co-deletion, O6-methylguanine DNA methyltransferase 
(MGMT) promoter methylation and IDH-1/2 mutation.14 Deletion of the entire chromosomal arms 1p and 19q 
(1p/19q co-deletion) detected by fluorescence in situ hybridisation (FISH) or microsatellite-based PCR for LOH 
or multiplex ligation-dependent probe amplification (MLPA) is a typical molecular lesion of oligodendroglial 
tumors. It is associated with improved prognosis, a less aggressive course of disease and favorable responses to 
radiotherapy and alkylating agent chemotherapy, or both.15-19 The demonstration of promoter methylation of the 
MGMT gene assessed by methylation-specific PCR or pyrosequencing of bisulfite-modified DNA is associated 
with superior outcome in anaplastic glioma patients treated with radiotherapy or alkylating agent 
chemotherapy19,20 and with specific benefit from temozolomide (TMZ) in glioblastoma patients.21-24 Retesting 
the MGMT status at recurrence is not necessary since the methylation status remains stable, at least in 
glioblastoma,25,26 moreover, a prognostic or predictive value of the MGMT status at recurrence is less well 
defined. 
Mutations of the IDH-1 or -2 genes are found in up to 80% of patients with diffuse gliomas of WHO grades II 
and III as well as in secondary glioblastomas (WHO grade IV), defined as glioblastomas derived from 
progression of a lower grade glioma. In contrast, IDH-1/2 mutations are only detected in 5-10% of tumors from 
patients with primary glioblastoma and never in pilocytic astrocytomas or ependymomas. Thus the assessment of 
the IDH-1/2 mutation status provides primarily diagnostic information. Within each tumor category, IDH-1/2-
mutant tumors have a better prognosis. The IDH-1/2 status can be assessed by PCR and (pyro)sequencing; 
moreover, the most common mutant variant, IDH-1R132H, can be detected by immunohistochemistry. While a 
firm role for the IDH-1/2 status in clinical decision making remains to be established, it may in the future 
provide a biological basis for molecularly based separation of diffuse grade II/III gliomas and primary 
glioblastomas.  
IDH-1/2 mutations are associated with the glioma CpG island methylator phenotype (G-CIMP), a molecular 
phenotype associated with a favourable outcome, too. We expect that high-throughput analyses may sequentially 
supplement and gradually replace single marker assessment. 
 
 
Therapy - General recommendations 
 
Surgical therapy 
While stereotactic surgical interventional strategies commonly serve diagnostic purposes, open neurosurgical 
operations are performed with therapeutic intention, depending on patient age, suspected diagnosis and tumor 
localization. Stereotactic biopsies are preferred for difficult tumor locations, multiple lesions, and frail patients in 
poor general condition where the risk of surgery-associated morbidity is high. The primary therapeutic goals of 
surgery for high-grade supratentorial gliomas are to remove the solid tumor mass as feasible, to relieve 
intracranial pressure and to restore or maintain neurological function. Microsurgical techniques are now standard 
of care. Neuronavigation, ultrasound, MRI and fluorescent agents have been employed to localize tumor tissue 
intraoperatively. The role of fluorescence-guided resection using 5-aminolevulinic acid (ALA) in achieving a 
higher rate of gross total resections translating into improved progression-free survival at 6 months was 
demonstrated in a prospective randomized clinical trial,11 resulting in approval of 5-ALA in the European Union. 
Efforts at resections in eloquent areas should be supported by monitoring brain function using, e.g., motor 
evoked potentials, somatosensory evoked potentials, electromyography or mapping and monitoring in awake 
patients using local anesthesia to assess and preserve language and cognitive functions. The avoidance of new 
neurological deficits should take higher priority than the extent of resection because malignant gliomas cannot be 
cured by surgery, and quality of life is emerging as a significant prognostic factor and is of major importance for 
patients. The overall therapeutic impact of surgical treatment of gliomas is limited by tumor cell infiltration 
beyond the macroscopically visible lesion, a biological hallmark of these tumors. This limits the extent and 
efficacy of all current surgical approaches. To determine and to document the outcome of surgical resections for 
gliomas and to recognize early postoperative complications, it is recommended to obtain an early postoperative 
MRI without and with contrast enhancement within 48-72 hours of surgery.27 If MRI is not available or in case 
of contraindications, a CT without and with contrast agent should be performed. 
 
Radiotherapy 
Despite the diffusely infiltrating nature, most gliomas grow macroscopically as a unifocal lesion and recur at the 
same site. Local control of tumor growth is therefore highly relevant. Radiotherapy has been demonstrated to 
prolong life while maintaining quality of life, specifically in patients with low residual tumor burden. Indication 
for, and dosing and scheduling of radiotherapy, depend on the histological grading according to the WHO 
classification and prognostic factors such as age, Karnofsky performance score (KPS) and extent of resection. 
Radiotherapy for malignant gliomas is commonly given to a total dose of 60 Gy in 1.8-2 Gy fractions, critical 
brain areas may be protected by limiting the dose there to 54 Gy. Modern techniques of focused radiotherapy, 
e.g. stereotactic radiotherapy, radiosurgery, intensity-modulated radiotherapy (IMRT) or image-guided 
radiotherapy improve the accuracy and localization of radiotherapy delivery. They may allow higher doses to be 
delivered safely, or standard doses to be prescribed with reduced irradiation of healthy areas of brain in 
comparison with conventional radiotherapy. However, randomized trials to confirm the superiority of these 
novel techniques over standard treatment have not been performed. The same is true for differential types of 
radiation. Previous trials on dose intensification beyond 60 Gy or the combination with stereotactic radiosurgery 
or brachytherapy were negative in glioblastoma. 
Whole brain radiotherapy of circumscribed gliomas increases morbidity, but does not improve control over local 
conformal radiotherapy of the involved tumor region and is therefore contraindicated. Targeted radiotherapy 
focused on the tumor region reduces morbidity, and may permit higher (and repeated) irradiation doses.  
When planning treatment, the area of residual enhancement on T1 imaging plus the surgical bed is first 
delineated as the gross tumor volume (GTV). A margin, typically 1.5 to 2.5 cm including the hyperintensity on 
T2 / FLAIR imaging is added to define the clinical target volume (CTV), which is then modified in areas where 
microscopic spread is unlikely, e.g. across the intact falx or into bone, or to reduce the dose to a critical structure, 
e.g. optic chiasm or brainstem. Finally a further margin, usually 0.5 cm, is added to allow for any movement 
during treatment, which generates the planning target volume (PTV). 
After microsurgical resection of a malignant glioma, the normal surrounding tissue may exhibit contrast 
enhancement caused by the surgical procedures which cannot be distinguished from residual or recurrent tumor 
on CT or MRI. The identification of tumor tissue for radiation planning is challenging in such situations. Early 
postoperative DWI MRI may identify ischemic lesions around the surgical cavity. Novel approaches try to base 
the determination of the target volume on PET using amino acid tracers such as 11C-MET or 18F-FET28,29 or MRI 
spectroscopy using choline/N-acetylaspartate metabolite cartography.5,30 
Several studies have shown that PET plus MRI will identify a different target volume compared to MRI alone. 
Whether radiation planning based on PET plus MRI compared with MRI alone results in superior outcome for 
the patients remains to be demonstrated in a randomized fashion. 
Exact and reproducible positioning of the patients during planning and conduct of radiotherapy using an 
immobilisation device, mask or frame, is essential. Planning requires the acquisition of a dedicated MRI or CT in 
irradiation position, the image-guided adaptation of isodose distribution to the target volume and transfer via a 
therapy simulator. A three-dimensional dose adaptation is highly recommended. The dose specification follows 
the International Commission on Radiological Units (ICRU) 50/62 with reference to the isodose surrounding the 
target volume and maximum dose. Minimal documentation requirements consist of dose distribution in the three 
planes, digital or simulation imaging, and portal imaging to confirm the reproducibility of the therapy fields of 
irradiation. 
The irradiation tolerance of normal brain depends, amongst others, on the fractionation. The TD 5/5 (Tolerance 
dose 5/5, adverse effect risk of 5% within 5 years) with conventional fractionation in single doses of 1.8–2 Gy is 
estimated to be 60 Gy administered over 6 weeks. The tolerated dose of radiosensitive structures such as optic 
nerve, chiasm, eye, brain stem or inner ears needs to be considered, and doses to these structures should be 
calculated and documented. Shorter courses of radiotherapy with higher fraction sizes are appropriate in older 
patients and those with poor prognostic factors, but necessitate reduction of the total dose, e.g., to 15 x 2.66 Gy, 
which is biologically equivalent. 
 
Pharmacotherapy 
Classical cytotoxic chemotherapy is an established treatment modality for patients with malignant gliomas. 
Normal blood cell counts, adequate liver and renal function and the absence of severe pulmonary or cardiac 
disease or active infection are required prior to therapy. Regular monitoring of blood counts is required during 
chemotherapy. The most commonly used agent, TMZ, is usually well tolerated.31-33 TMZ does not have 
cumulative myelotoxicity, but seldom causes early grade 4 myelotoxicity necessitating dose reduction or even 
definitive discontinuation. Since TMZ may rarely induce severe liver damage, regular monitoring of liver 
enzymes is recommended. In cases of suspected TMZ-induced alveolitis, chemotherapy should be stopped, and 
should not be resumed if the diagnosis has been confirmed. Nitrosoureas such as lomustine (CCNU) can induce 
prolonged leukopenia and thrombopenia, requiring dose reductions for the subsequent cycles, or a change of 
regimen. The risk of pulmonary fibrosis may be higher with carmustine (BCNU). Nitrosoureas are now agents of 
second choice relative to TMZ for glioma treatment in most countries in Europe. Several experimental 
pharmacological agents are currently being explored for efficacy in malignant gliomas, in particular in the field 
of angiogenesis inhibition. At present only bevacizumab, an antibody to vascular endothelial growth factor 
(VEGF), is approved for the treatment of patients with recurrent glioblastoma in the USA, Canada, Switzerland 
and various other countries, although not in the European Union. To monitor chemotherapy it is advisable to 
provide the patients with an adequate document sometimes referred to as a chemotherapy pass where the results 
of laboratory controls and unusual observations of the patients or other comments can be documented. 
Institutions involved in the care of malignant glioma patients should have written guidelines and standard 
operating procedures how to deal with the most severe complications listed above. 
The standard duration of TMZ chemotherapy is 6 cycles for newly diagnosed glioblastoma in combination with 
radiotherapy. In case of efficacy defined as complete or partial response or stable disease, alkylating agent 
chemotherapy administered as a single treatment either for newly diagnosed or recurrent disease is commonly 
stopped after 8-12 cycles of TMZ or 4-6 cycles of nitrosourea-based chemotherapy, however, the optimal 
treatment duration has never been formally evaluated in patients with recurrent gliomas. Bevacizumab for 
recurrent gliomas is commonly given until progression. 
 
Other therapeutic approaches 
New approaches of glioma therapy including suicide gene therapy, various approaches of immunotherapy, or 
device-based therapies such as tumor-treating fields (TTF)34 or electromagnetic nanotherapy should only be 
administered in the context of clinical trials. The approval of the latter in the EU concerns their status as devices 
and is based on safety, but not efficacy. 
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examination 
and imaging 
 Unfavorable prognostic 
factors: 
ο KPS < 70 
 Surgery 
 Radiotherapy 
(hypofractionated) 
 Age > 65-70 
MGMT promoter non-
methylated 
 Surgery 
 Radiotherapy 
(hypofractionated) 
 Age > 65-70 
MGMT promoter 
methylated 
 Surgery 
 Chemotherapy 
(±Radiotherapy) 
 Very unfavorable prognostic factors: 
ο KPS < 50 
or 
 Inability to consent 
 
